WAT icon

Waters Corp

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 65.5%
Negative

Neutral
Seeking Alpha
19 hours ago
Artisan Mid Cap Fund Q1 2026 Portfolio Activity
During the quarter, we initiated new positions in Semtech, Tradeweb Markets and SiTime. We also added to Edwards Lifesciences, Waters and Arthur J. Gallagher during the quarter. We ended our investment campaigns in Ares, CCC Intelligent Solutions and Parsons during the quarter.
Artisan Mid Cap Fund Q1 2026 Portfolio Activity
Neutral
PRNewsWire
yesterday
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3 Achieves 10x improvement in absolute molar mass and extended sizing, without compromising resolution or analytical throughput.2 Reduces sample consumption by 30-50% and solvent use by approximately 40%.3 MILFORD, Mass., April 14, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Positive
Benzinga
7 days ago
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
Waters Corporation (NYSE:WAT) shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV Self-Collection Kit, a significant step in expanding access to cervical cancer screening.
Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit
Neutral
PRNewsWire
7 days ago
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection reduces significant barriers for unscreened or under-screened individuals who make up approximately 60% of cervical cancer cases.3 Waters is establishing partnerships to enable broader nationwide access to the Onclarity™ HPV Self-Collection Kit for patients and prescribers to reduce cervical cancer risk.
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
Neutral
Seeking Alpha
7 days ago
ClearBridge Dividend Strategy Q1 2026 Portfolio Positioning
We bought four “new” holdings in the quarter. Two of the four — Blackstone and Otis — we have owned before. In IT, we exited Oracle and trimmed Broadcom. Our five-year investment in Oracle proved highly profitable as the company transitioned its business model from licensing to software-as-a-service. On the semiconductor side, we modestly reduced our position in Broadcom to fund our new investment in Taiwan Semiconductor.
ClearBridge Dividend Strategy Q1 2026 Portfolio Positioning
Neutral
PRNewsWire
28 days ago
Waters Prices Offering of Senior Notes
MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation ("Augusta"): $650 million aggregate principal amount of 4.321% Senior Notes due 2027 at the issue price of 100.000% of their principal amount; $600 million aggregate principal amount of 4.398% Senior Notes due 2029 at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of 4.656% Senior Notes due 2031 at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of 4.945% Senior Notes due 2033 at the issue price of 100.000% of their principal amount; and $750 million aggregate principal amount of 5.245% Senior Notes due 2036 at the issue price of 100.000% of their principal amount (collectively, the "Notes").
Waters Prices Offering of Senior Notes
Negative
Zacks Investment Research
1 month ago
Waters (WAT) Down 8.4% Since Last Earnings Report: Can It Rebound?
Waters (WAT) reported earnings 30 days ago. What's next for the stock?
Waters (WAT) Down 8.4% Since Last Earnings Report: Can It Rebound?
Neutral
PRNewsWire
1 month ago
Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed
News Summary: Reduces standard testing times by 80%.1 Delivers an industry-leading 25,000 data points per second, detecting transient material behaviors previously invisible to measurement. 2 Operates with fewer calibrations and superior atmosphere and temperature control.
Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed
Positive
Zacks Investment Research
1 month ago
Waters (WAT) Upgraded to Buy: What Does It Mean for the Stock?
Waters (WAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Waters (WAT) Upgraded to Buy: What Does It Mean for the Stock?
Positive
Zacks Investment Research
1 month ago
Down 19% in 4 Weeks, Here's Why You Should You Buy the Dip in Waters (WAT)
The heavy selling pressure might have exhausted for Waters (WAT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 19% in 4 Weeks, Here's Why You Should You Buy the Dip in Waters (WAT)